title: In vitro activity of RX-P873 against Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii.
abstract: RX-P873 is a novel antibiotic from the pyrrolocytosine series which exhibits high binding affinity for the bacterial ribosome and broad-spectrum antibiotic properties. The pyrrolocytosines have shown in vitro activity against multidrug-resistant Gram-negative and Gram-positive strains of bacteria known to cause complicated urinary tract, skin, and lung infections, as well as sepsis. Enterobacteriaceae (657), Pseudomonas aeruginosa (200), and Acinetobacter baumannii (202) isolates from North America and Europe collected in 2012 as part of a worldwide surveillance program were tested in vitro by broth microdilution using Clinical and Laboratory Standards Institute (CLSI) methodology. RX-P873 (MIC90, 0.5 μg/ml) was >32-fold more active than ceftazidime and inhibited 97.1% and 99.5% of Enterobacteriaceae isolates at MIC values of ≤1 and ≤4 μg/ml, respectively. There were only three isolates with an MIC value of >4 μg/ml (all were indole-positive Protea). RX-P873 (MIC50/90, 2/4 μg/ml) was highly active against Pseudomonas aeruginosa isolates, including isolates which were nonsusceptible to ceftazidime or meropenem. RX-P873 was 2-fold less active against P. aeruginosa than tobramycin (MIC90, 2 μg/ml; 91.0% susceptible) and colistin (MIC90, 2 μg/ml; 99.5% susceptible) and 2-fold more potent than amikacin (MIC90, 8 μg/ml; 93.5% susceptible) and meropenem (MIC90, 8 μg/ml; 76.0% susceptible). RX-P873, the most active agent against Acinetobacter baumannii (MIC90, 1 μg/ml), was 2-fold more active than colistin (MIC90, 2 μg/ml; 97.0% susceptible) and 4-fold more active than tigecycline (MIC90, 4 μg/ml). This novel agent merits further exploration of its potential against multidrug-resistant Gram-negative bacteria.
authors: JMI Laboratories, North Liberty, Iowa, USA robert-flamm@jmilabs.com.
authors: Robert K
authors: RK
authors: Flamm
authors: JMI Laboratories, North Liberty, Iowa, USA.
authors: Paul R
authors: PR
authors: Rhomberg
authors: JMI Laboratories, North Liberty, Iowa, USA Tufts University School of Medicine, Boston, Massachusetts, USA.
authors: Ronald N
authors: RN
authors: Jones
authors: JMI Laboratories, North Liberty, Iowa, USA Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
authors: David J
authors: DJ
authors: Farrell
mesh_terms: D040981:Acinetobacter baumannii / Q000187:drug effects*; D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D004755:Enterobacteriaceae / Q000187:drug effects*; D006146:Guanidines / Q000737:chemistry / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D011744:Pyrimidinones / Q000737:chemistry / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D006146:Guanidines; D011744:Pyrimidinones; C000603506:RX-P873
references: Clin Infect Dis. 2009 Jan 1;48(1):1-12
references: 19035777
references: Infect Control Hosp Epidemiol. 2010 May;31(5):528-31
references: 20334552
references: J Antimicrob Chemother. 2011 Feb;66(2):398-407
references: 21106563
references: Clin Infect Dis. 2013 Jun;56(12):1685-94
references: 23599308
references: J Antimicrob Chemother. 2013 Mar;68(3):490-1
references: 23152481
references: Antimicrob Agents Chemother. 2013 Apr;57(4):1971-3
references: 23357768
references: N Engl J Med. 2012 Feb 2;366(5):454-61
references: 22296079